DOCSLIB.ORG

Openvape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Openvape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents Research Article: Open Source Tools and Methods | Novel Tools and Methods OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents https://doi.org/10.1523/ENEURO.0279-20.2020 Cite as: eNeuro 2020; 10.1523/ENEURO.0279-20.2020 Received: 27 June 2020 Revised: 30 July 2020 Accepted: 18 August 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 Frie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Manuscript Title Page Instructions 2 1. Manuscript Title (50 word maximum) 3 4 OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents 5 2. Abbreviated Title (50 character maximum) 6 7 OpenVape: an Open-Source Vapour Exposure Device 8 3. List all Author Names and Affiliations in order as they would appear in the published article 9 10 Jude A. Frie – Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 11 Ontario, Canada. 12 Jacob Underhill – Department of Biomedical Sciences, Ontario Veterinary College, University of 13 Guelph, Ontario, Canada. 14 Bin Zhao – Departments of Pharmacology and Toxicology, University of Toronto, Ontario, Canada 15 Giordano de Guglielmo – Department of Psychiatry, University of California, San Diego, San Diego, 16 California, USA. 17 Rachel F. Tyndale – Departments of Pharmacology and Toxicology, and Psychiatry, University of 18 Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Canada. 19 Jibran Y. Khokhar – Department of Biomedical Sciences, Ontario Veterinary College, University of 20 Guelph, Ontario, Canada. 21 4. Author Contributions: JAF, JU and JYK: Designed Research, Performed research, Contributed 22 unpublished reagents/ analytic tools, Analyzed data, Wrote the paper. BZ: Performed Research. 23 GdG: Designed Research. RFT: Performed Research, Wrote the Paper. 24 25 5. Correspondence should be addressed to (include email address) 26 27 Dr. Jibran Khokhar 28 Department of Biomedical Sciences 29 Ontario Veterinary College 30 University of Guelph 31 50 Stone Rd. E. 32 Guelph, ON 33 N1G1C5 34 [email protected] 35 36 1 37 38 6. Acknowledgements 39 We would like to thank Judy Chen and Ariel Oren for their assistance with CPP 40 experiments. 41 42 7. Conflict of Interest 43 44 A. No (State ‘Authors report no conflict of interest’) 45 46 B. Yes (Please explain) 47 48 Yes – RF Tyndale has consulted for Quinn Emanuel and Ethismos Research Inc on 49 unrelated topics. 50 8. Funding sources 51 This work was supported by a Discovery Grant from the Natural Sciences and Engineering 52 Research Council award (RGPIN-2019-05121) to JYK. This research was undertaken, in 53 part, thanks to funding from the Canada Research Chairs program (RFT, CRC in 54 Pharmacogenomics) and a Canadian Institutes of Health Research (Foundation grant FDN- 55 154294). 56 1 57 58 Visual Abstract 59 60 Abstract 61 The prevalence of "vaping" has recently seen significant increases in North America, especially 62 in adolescents. However, the behavioural correlates of vaping are largely unexplored. The uptake 63 of existing technologies meant for rodent vapour inhalation remains limited due to a lack of 64 affordability and versatility (ability to be used with a variety of vapourizers). The OpenVape 65 offers an open-source, low-cost solution that can be used in a variety of research contexts. Here 66 we present a specific use case, combining the OpenVape apparatus with JUUL e-cigarettes. This 67 apparatus consists of Arduino-operated vacuum pumps that deliver vapour directly from e- 68 cigarettes to exposure chambers. The OpenVape is easy to build and customize for any type of 69 vapourizer (e.g., nicotine pod or tank; cannabis flower or concentrates). To test the OpenVape, 70 we performed biochemical verification and behavioural studies. The behavioural test 2 71 (conditioned place preference) was conducted using adolescent and adult animals to assess 72 developmental differences in the rewarding effects of nicotine vapour, as previously observed 73 with injected nicotine. These findings demonstrate that even after brief exposures to nicotine 74 vapour, pharmacologically relevant nicotine and cotinine levels could be detected in plasma, and 75 significant conditioned place preference was observed, especially in adolescent rats which 76 showed preference at shorter puff delivery durations (lower nicotine doses) compared to adults. 77 Together, these findings suggest that OpenVape provides an affordable, open-source option for 78 pre-clinical behavioural research into the effects of vaping. 79 Significance Statement 80 With the recent increases in popularity of vaping, behavioural and neurobiological studies in 81 preclinical models will be pivotal in exploring the impacts of this use. While there are 82 commercially available vapour exposure equipment, they can be prohibitively expensive and 83 often require proprietary software. The OpenVape (OV) is able to deliver regulated doses of 84 vapour into a standard animal cage with minimal operator intervention. The OV is also open- 85 source, easy to build, inexpensive, and can be used in a variety of research contexts due to its 86 small physical footprint. In this study, we validate its efficacy using JUUL e-cigarettes, showing 87 that animals achieve meaningful nicotine levels, and that both adolescent and adult animals 88 display conditioned place preference to the nicotine vapour. 89 Introduction 90 In recent years, adolescent e-cigarette use has increased dramatically, with past 30-day nicotine 91 vaping among US high school students growing from 11.7% to 27.5% between 2017 and 2019 92 (Wang et al., 2019). Currently, the most popular e-cigarette is the JUUL, maintaining 76% of the 3 93 US e-cigarette market (Craver, 2019). JUUL’s adolescent appeal has been attributed to their 94 sleek/discreet design (Kavuluru et al., 2019). influential marketing (Mantey et al., 2016; Huang 95 et al., 2019), appealing flavours (Leavens et al., 2019), and high nicotine content (Kong et al., 96 2019). Additionally, JUUL’s have been shown to deliver significantly more nicotine to the 97 bloodstream compared to traditional cigarettes (Rao et al., 2020). 98 Adolescence is thought to be a period of increased sensitivity to the rewarding effects of nicotine 99 (Thorpe et al., 2020). Indeed, nearly 90% of cigarette smokers initiate smoking before the age of 100 18 (Substance Abuse and Mental Health Services Administration, 2013). Adolescent smokers 101 also increase cigarette intake faster than adults (DiFranza et al., 2000), and report more positive 102 and less aversive experiences to initial cigarette exposures (Benowitz, 1999) Animal studies 103 support this data, with adolescent animals consistently showing both greater preference, and 104 preference across a larger range of doses during nicotine conditioned place preference (CPP) 105 compared to adults, a measure of the reward-like (hedonic value) properties of a drug (Vastola et 106 al., 2002; Belluzzi et al., 2004; Shram et al., 2006; Brielmaier et al., 2007; Kota et al., 2007, 107 2008; Torres et al., 2008; Shram and Lê, 2010; Ahsan et al., 2014). While beneficial in 108 understanding the rewarding effects of nicotine, these studies may not capture what makes 109 nicotine vapour rewarding in adolescents. The current study improves upon the translatability of 110 findings by directly exposing rats to the most popular e-cigarette available – JUUL. No studies to 111 date have assessed the developmental differences in nicotine vapour preference, partly owing to 112 limited options for exposing rodents to nicotine vapour. 113 Current commercially available nicotine vapour exposure apparatuses (e.g. DSI Buxco, SCIREQ 114 inExpose, LJARI eVape) are prohibitively expensive and require proprietary hardware and 115 software to operate, thereby limiting their accessibility and versatility. This has led others to 4 116 create customized alternatives (Manwell et al., 2014; Liu et al., 2016; Nguyen et al., 2016; Hage 117 et al., 2017; Lefever et al., 2017; Hilpert et al., 2019). However, these alternatives are still very 118 expensive, complicated to construct, and are not always open-source. Thus, in order to address 119 these issues, we created OpenVape (OV) – an affordable, open-source vapour delivery system. 120 OV can be made for ~$230, is easily constructed/operated, and is highly versatile (can be used 121 with a variety of vaping devices and products). It is also open-source, encouraging the 122 community to continue to add functionality as required. Here we provide the instructions to build 123 the simplest version of OV and provide a relevant behavioural validation showing the 124 developmental differences in nicotine’s reward-like properties during a CPP task. We also show 125 that OV is capable of producing pharmacologically relevant blood nicotine and cotinine levels 126 following short periods of vapour exposure. 127 Materials and Methods 128 Animals 129 For the pharmacokinetic study, 15 adult male Sprague (Charles River, Quebec) were used. These 130 rats were housed in pairs and given ad libitum access to standard chow and water. For the age- 131 dependent CPP study, a total of 48 male Sprague-Dawley rats were used, consisting of 24 adults 132 and 24 adolescents. These rats were housed in groups of 4 (to maintain consistency between 133 adult and adolescent rats) and given access to standard chow and water. All animal procedures 134 were performed in accordance with the [Author University] animal care committee's regulations. 135 Device Design 5 136 The OV device requires one standard wall receptacle for power.
Load more

Recommended publications
  • Effects of Combined THC and Heroin Vapor Inhalation
    Psychopharmacology https://doi.org/10.1007/s00213-021-05904-w ORIGINAL INVESTIGATION Efects of combined THC and heroin vapor inhalation in rats Arnold Gutierrez1,2 · Jacques D. Nguyen1,2 · Kevin M. Creehan1,2 · Mehrak Javadi‑Paydar1 · Yanabel Grant1,2 · Michael A. Tafe1,2 Received: 27 April 2021 / Accepted: 27 May 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 Abstract Rationale Opioids are efective medications, but they have several key limitations including the development of tolerance, establishment of dependence, diversion for non-medical use, and the development of addiction. Therefore, any drugs which act in an additive or synergistic fashion with opioids to address medical applications have the potential to reduce opioid- related harms. Objectives To determine if heroin and Δ9-tetrahydrocannabinol (THC) interact in an additive or independent manner to alter nociception, body temperature, and spontaneous locomotor activity when inhaled or injected. Methods Groups of female and male rats, implanted with radiotelemetry transmitters, were exposed to vapor generated from heroin (50 mg/mL in propylene glycol vehicle; PG), THC (50 mg/mL), or the combination for assessment of efects on temperature and activity. Thermal nociception was assessed with a warm water tail-withdrawal assay. Results Heroin inhalation increased temperature and activity whereas THC inhalation decreased temperature and activity in both female and male Sprague–Dawley rats. Efects of combined inhalation were in opposition, and additional experiments found the same outcome for the injection of heroin (0.5 mg/kg, s.c.) and THC (10 mg/kg, i.p.) alone and in combination.
    [Show full text]
  • How Adam Bierman Built Medmen Into an Influential Industry Player
    Creating a best-selling cannabis edible in a crowded market $12.95 VOL 4 • ISSUE 8 • September 2017 Crop storage+ strategies Vape industry overview Getting a grow NO off the ground APOLOGHow Adam Bierman built ¬ES MedMen into an influential industry player despite his blunt, controversial style 312.869.9070 IF YOU’RE NOT MESSAGING YOUR CUSTOMERS, THEN SOMEBODY ELSE IS! SMS is the best and most effective way to increase your daily store traffi c. Our clients say a blast brings in 10-50 incremental customers (per 1000 messaged). MESSAGING PAYS FOR ITSELF 10 TIMES OVER! A 420 sending number to increase Reliable delivery. No blocking. brand effectiveness. Excellent customer service. UP TO 240 CHARACTERS PER MESSAGE Need help building your opt in list? (50% more than others). More info to We got you covered. your customers means more sales. Great prices. Discounts for Picture messaging (MMS) available. higher volumes. No contracts or setup fees. 90% OF SMS ARE READ WITHIN 3 MINUTES OF RECEIPT. 4 20 YOU CAN’T AFFORD Thursday, April 20 NOT TO USE NORTHTEXT. Dispensary now SMS messaging expertise tailored specifi cally to the Dispensary market WWW.NORTHTEXT.COM/DISPENSARY | 312.869.9070 In business since 2007 Trim-8.375x10.875.qxp_Layout 1 1/20/17 10:22 AM Page 1 System 420™ Hybrid Greenhouses Larger Yields, Better Crops, Lower Costs PRODUCTION YIELDS With over 1 million square feet of Light deprivation, environmental controls, and benching systems Why Nexus? cannabis greenhouses constructed in provide the tools to optimize the 11 states, Nexus has developed unique expertise in designing grow system for high capacity integrated cannabis growing systems.
    [Show full text]
  • CAN2021 Abstracts
    CAN-ACN 2021 Submitted Abstracts ABOUT VISTA VISTA is a collaborative research program funded by the Canada First Research Excellence Fund (CFREF). VISTA builds on York University’s world- leading interdisciplinary expertise in biological and computer vision with over 80 academic, public, and for-profit partners. HIGHLIGHTS MISSION Our mission is to advance vision science through computational and biological research perspectives and to produce applications that generate positive economic, societal, health and technological impacts for Canada and the world. FUNDED TO DATE BECOME A VISTA AFFILIATE/PARTNER Program benefits: Become a member of an interdisciplinary research community across BECOME A VISTA TRAINEE the research areas of health, science, engineering, humanities, & arts Master's Scholarships Work with over 80 industry partners offering opportunities for research 2 year funding ($10,000/year), in addition collaboration and product development to standard York University funding Supervisor must be a VISTA Core member Join an international network pushing the boundaries of vision PhD Scholarships research in North America, Europe, and Asia 4 year funding ($10,000/year), in addition to standard York University funding Collaborate on VISTA-funded research projects Supervisor must be a VISTA Core member Postdoctoral Fellows Participate in VISTA-funded events 2 year funding ($55,000/year) Yearly Research and Networking allowances Travel Awards to support expenses for visiting scholars, students, and fellows to/from current VISTA partners CONTACT/FOLLOW US [email protected] @vistayorku Visit us: yorku.ca/vista Contents Parallel symposium 1: Neurovascular function in health and disease .......................................... 1 Parallel symposium 2: The hypothalamus and its hormones in health & disease......................
    [Show full text]
  • The “Green Gold Rush”
    ACKRELL CAPITAL U.S. CANNABIS INVESTMENT REPORT 2016 The “Green Gold Rush” Contents n Foreword I Executive Summary II Legislative Landscape; Legal Issues for Investor Consideration III Cannabis 101 IV U.S. Cannabis Market Estimates Overview V Industry Segmentation VI Capital Markets for Cannabis Companies • Cannabis is federally illegal in the United States. However, as of VII Top 100 Private Cannabis Companies 2016 the date of this report, 39 states have legalized cannabis in some form for recreational or medicinal use. VIII Industry Risk Factors • The current consumer market for recreational and medicinal IX Glossary of Terms cannabis in the United States is estimated to be more than n Disclosures, Disclaimers, Sources and Use of This Report $40 billion, including both legal and illegal consumption. n Ackrell Capital Team Leaders • We believe that it is a question of when—not if—the federal prohibition on cannabis will end. In analyzing how the end of n Inside Back Cover: The Green Field 2016 prohibition may affect the cannabis industry, we have assumed that prohibition ends by 2020. However, even with federal pro- hibition, the cannabis industry today is large and dynamic. About Ackrell Capital • We estimate that the U.S. cannabis consumer market for legal- ized recreational and medicinal use was $4.4 billion in 2015 Founded in 2003, Ackrell Capital is a leading independent invest- and will grow to $9.5 billion in 2019. Once legalized federally, ment bank focused on emerging growth companies. Ackrell Capi- we estimate this market will grow to $37 billion within 5 years tal’s principals have completed more than 300 corporate finance and $50 billion within 10 years.
    [Show full text]
  • 2021 Meeting Abstractsts
    College on Problems of Drug Dependence (CPDD) Virtual Scientific Meeting, June 21-24, 2021 *All times are listed in the Eastern U.S. Time Zone Monday, June 21, 2021 Late-Breaking Oral Presentations I Initial Results From STAMPOUT: Study of IXT-M200 in Non-Treatment Seeking Persons Who Use Methamphetamine W. Brooks Gentry*1, Lynn Webster2, Keith Ward1, Misty Stevens1 1InterveXion Therapeutics, LLC; University of Arkansas for Medical Sciences, 2PRA Health Sciences Drug Category Stimulants Topic Substance Use Disorder Abstract Detail Human Abstract Category Original Research Aim: IXT-m200 is a high-affinity, anti-methamphetamine (METH) antibody. The aim of this study was to determine the safety, tolerability and pharmacokinetics (PK) of single IV doses of IXT-m200 followed by weekly IV METH challenges in subjects with METH use disorders. The impacts of IXT-m200 on METH PK and on METH effects as measured by drug effects questionnaires (DEQ) were determined. Methods: This was a parallel-group, placebo-controlled, double-blind study in otherwise healthy, non-treatment seeking participants. Subjects were required to discriminate METH (30 mg, IV) from placebo with DEQ to qualify. Those who qualified received single doses of IXT-m200 (6 or 20 mg/kg) or placebo followed by weekly METH challenges for up to 4 weeks. The challenges consisted of METH (30 mg, IV) and placebo, separated by 4 hr. Safety, METH and IXT-m200 PK, and DEQ data were collected for up to 126 days. Results: 56 subjects were included in the pharmacokinetic and safety sets, with 20 receiving the IXT-m200 placebo, 18 receiving 6 mg/kg and 18 receiving 20 mg/kg IXT-m200.
    [Show full text]
  • Marijuana Business Con Erence & Expo®
    Marijuana Business Conerence & Expo® #MJBizCon There’s a better way to navigate the challenges of the cannabis industry... MJardin is uniquely positioned to provide long-term cultivation solutions that increase yields, decrease costs, and add profits to your bottom line. We are cultivators, not consultants. Visit us: MJardin.com Table of Contents Conference Access Icons Your name badge displays icons to indicate your conference access. Use the key below to determine which events you have access Attendee Guidelines .............................................................................................................5 to. To purchase any separately ticketed events, please see a staff member at registration. Who’s Behind This Conference .........................................................................................6 From the Publisher ................................................................................................................7 MJBizCon Through the Years ...........................................................................................8 Conference Sessions OVERFLOW & Expo Halls Wednesday Sessions in Penn & Teller Theater Thank You to Our Sponsors .............................................................................................12 & Expo Halls Agenda-at-a-Glance ............................................................................................................16 W Expo Hall Access WEDNESDAY ONLY Full Agenda & Session Descriptions ............................................................................24
    [Show full text]
  • Alcohol and Vapourized Nicotine Co-Exposure During Adolescence Contribute
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.23.449629; this version posted June 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Alcohol and Vapourized Nicotine Co-Exposure During Adolescence Contribute Differentially to Sex-Specific Behavioural Effects in Adulthood Jessica Ruffolo1,2*, Jude A. Frie1,2*, Hayley H.A. Thorpe1,2, M. Asfandyaar Talhat1, Jibran Y. Khokhar1,2 1 Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada 2 Collaborative Neurosciences Graduate Program, University of Guelph, Guelph, ON, Canada * Both authors contributed equally to this work Corresponding Author: Jibran Y. Khokhar, Ph.D. [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.06.23.449629; this version posted June 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Introduction: Co-occurrence of e-cigarette use and alcohol consumption during adolescence is frequent. However, little is known about their long-lasting effects when combined. Here, we examined whether adolescent co-exposure to alcohol drinking and vapourized nicotine would impact reward- and cognition-related behaviours in adult male and female rats during adulthood. Methods: Four groups of male and female Sprague Dawley rats (n=8-11/group/sex) received either nicotine (JUUL 5% nicotine pods) or vehicle vapour daily between postnatal days 30-46, while having continuous voluntary access to ethanol and water during this time in a two-bottle preference design.
    [Show full text]
  • The Newface of Big Tobacco
    The new face of Big Tobacco Say NO to Big Marijuana in New Zealand. Don’t Legalise. BRIEFING FOR FAMILIES First Edition February 2019 The new face An Important Resource For Familiesof Big Tobacco Same corporates. WE’VE BEEN SUCKED IN ONCE. Same objectives. Remember Big Tobacco? Tobacco companies lied to New Zealanders Same addiction. and the world for more than a century about the dangers of smoking. New product. They based their market on addiction. They deliberately targeted kids. They even had doctors promote cigarettes as medicine. And today we are paying the price. The conversation is now being dictated by Big Marijuana, who will deny evidence-based science, and will minimise harms by emphasising the economic benefits of large tax revenues. Sound familiar? Ultimately, they’re not in it for the health of your family – Image Source: tobacco.stanford.edu they’re in it to make big money. But people should always come before profits. Because of the lobbying of pro-drug advocates such as the Drug Foundation and the Green Party - and the coalition agreement between Labour, Greens and NZ First made after the last Election - we will be voting on legalising marijuana at the next General Election in 2020 (around September). We know that if marijuana is legalised, a commercial marijuana industry will act just as the tobacco industry acts – irrespective of any ‘regulations’. Today’s highly potent marijuana represents a growing and significant threat to public health and safety, a threat that is amplified by a new marijuana industry intent on profiting from heavy use.
    [Show full text]
  • Effects of Combined THC and Heroin Vapor Inhalation in Rats
    UC San Diego UC San Diego Previously Published Works Title Effects of combined THC and heroin vapor inhalation in rats. Permalink https://escholarship.org/uc/item/7mw911h2 Authors Gutierrez, Arnold Nguyen, Jacques D Creehan, Kevin M et al. Publication Date 2021-06-23 DOI 10.1007/s00213-021-05904-w Peer reviewed eScholarship.org Powered by the California Digital Library University of California Psychopharmacology https://doi.org/10.1007/s00213-021-05904-w ORIGINAL INVESTIGATION Efects of combined THC and heroin vapor inhalation in rats Arnold Gutierrez1,2 · Jacques D. Nguyen1,2 · Kevin M. Creehan1,2 · Mehrak Javadi‑Paydar1 · Yanabel Grant1,2 · Michael A. Tafe1,2 Received: 27 April 2021 / Accepted: 27 May 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 Abstract Rationale Opioids are efective medications, but they have several key limitations including the development of tolerance, establishment of dependence, diversion for non-medical use, and the development of addiction. Therefore, any drugs which act in an additive or synergistic fashion with opioids to address medical applications have the potential to reduce opioid- related harms. Objectives To determine if heroin and Δ9-tetrahydrocannabinol (THC) interact in an additive or independent manner to alter nociception, body temperature, and spontaneous locomotor activity when inhaled or injected. Methods Groups of female and male rats, implanted with radiotelemetry transmitters, were exposed to vapor generated from heroin (50 mg/mL in propylene glycol vehicle; PG), THC (50 mg/mL), or the combination for assessment of efects on temperature and activity. Thermal nociception was assessed with a warm water tail-withdrawal assay.
    [Show full text]
  • Dispensary Selection Information
    ______________________________________________________________________________________ State of Vermont Department of Public Safety Marijuana Registry [phone] 802-241-5115 45 State Drive [fax] 802-241-5230 Waterbury, Vermont 05671-1300 [email] [email protected] www.medicalmarijuana.vermont.gov Dispensary Selection Information IMPORTANT INFORMATION CONTAINED BELOW WHEN COMPLETING THE FORMS TO REGISTER AS A PATIENT WITH THE VERMONT MARIJUANA REGISTRY (VMR). Materials provided by each dispensary are attached to assist patient applicants designating a dispensary. Registered patients may purchase marijuana, marijuana infused products, seeds, and clones from a registered dispensary. Registered patients who designate a dispensary may purchase marijuana products and cultivate marijuana in a single secure indoor facility. Registered patients who elect to cultivate marijuana in a single secure indoor facility must provide the address and location to the VMR on his or her application. Any updates to the address and/or location of the single secure indoor facility must be submitted in writing via email or mail to the contact information below. Registered patients may only purchase marijuana, marijuana infused products, seeds, and clones from one dispensary and must designate the dispensary of his or her choice on their application. Registered patients may only change dispensaries every 30 days. After 30 days, a registered patient may change his or her designated dispensary by submitting a completed Cardholder Information Notification form and a $25 processing fee. The VMR will issue the registered patient a new registry identification card with a new registry identification number. ALL registered patients and caregivers MUST schedule appointments prior to going to their designated dispensary to obtain marijuana, this includes seed and clones.
    [Show full text]
  • Holiday Gift Guide Enter to Win This Box! Recipes
    ISSUE 19 | CA. CO. OR. WA TEXT “EDIBLES” TO 63975 TO WIN THIS GIFT BOX RECIPES, REVIEWS & MORE ENTER TO WIN THIS BOX! HOLIDAY GIFT GUIDE 1 2 3 TEXT “EDIBLES” TO 63975 TO WIN OUR MONTHLY GIVE-AWAY! EDIBLE DESTINATIONS: BELLA VISTA ESTATE & LOVE & MARIJ WEDDINGS............................ 38 COLORADO SECTION......................................... 39 DECEMBER infused recipes: CONTENTS Mighty Canna Cranberry Sauce, Infused Cranberry Pistachio Chocolate Bark, Food of The Gods Infused Chocolate Chip i s s u e 1 9 Coconut Oil Cookies, Mighty Medicated Maple Syrup Roasted Butternut the HOLIDAY issue Squash Soup, 420 Bangin Broccoli & Garlic.........................................40 CALIFORNIA SECTION................................................ 7 PRODUCT FEATURE: medible FEATURE: 420 GB & CANNABOX...................................... 42 SOMETHING chocolate.................................. 10 SHOP FEATURE: medible REVIEW: KINDMEDS............................................................ 44 INFUSED CINNAMON TOOTHPICKS............... 12 FOOD SCIENCE: medible feature: MALTODEXTRIN TO WHOM IT MAY IS IT GOOD OR BAD?......................................... 46 CANNABIS CHOCOLATES..................................... 14 COVER FEATURE: OREGON SECTION............................................... 49 SHADES OF GREEN DECEMBER EVENT GUIDE.............................. EDIBLES SUBSCRIPTION BOX........................... 19 51 MEDIBLE REVIEW: PRODUCT FEATURE: FORBIDDEN LEAF................................................. ZASP INFUSED DRINKS.....................................
    [Show full text]
  • Dispensary Selection Information
    ______________________________________________________________________________________ State of Vermont Department of Public Safety Marijuana Registry [phone] 802-241-5115 45 State Drive [fax] 802-241-5230 Waterbury, Vermont 05671-1300 [email] [email protected] www.medicalmarijuana.vermont.gov Dispensary Selection Information THE INFORMATION ATTACHED TO THIS DOCUMENT HAS BEEN PROVIDED BY THE DISPENSARIES TO ASSIST PATIENTS SELECTING A DISPENSARY. The information contained below is general information for applicants. Registered patients may purchase marijuana, marijuana infused products, hemp-infused products, seeds, and clones from a registered dispensary. Registered patients may designate a dispensary to purchase marijuana and may cultivate marijuana. Registered patients may only change dispensaries every 30 days. After 30 days, a registered patient may change his or her designated dispensary by submitting a completed Cardholder Update/Replacement ID Form and a $25 processing fee. The VMR will issue the registered patient a new registry identification card with a new registry identification number. ALL registered patients and caregivers MUST schedule appointments prior to going to their designated dispensary to obtain marijuana, this includes seed and clones. There are currently five registered dispensaries operating in Vermont; Champlain Valley Dispensary in Burlington and South Burlington, Grassroots Vermont in Brandon, PhytoCare Vermont in Bennington, and Vermont Patients Alliance in Montpelier. Contact the dispensary if you have questions related to products, pricing, and appointments. Contact the VMR with questions related to the information contained above. [Phone] (802) 241-5115 [Email] [email protected] [Website] MedicalMarijuana.vermont.gov _____________________________________________________________________________________ Welcome to Champlain Valley Dispensary & Southern Vermont Wellness We’re dedicated to providing high quality, laboratory-tested medical cannabis to our patients.
    [Show full text]